X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (40) 40
index medicus (39) 39
female (28) 28
middle aged (27) 27
oncology (27) 27
aged (19) 19
adult (15) 15
male (15) 15
prognosis (15) 15
cancer (13) 13
melanoma (12) 12
breast neoplasms - pathology (11) 11
therapy (11) 11
lymphatic metastasis (10) 10
immunohistochemistry (9) 9
aged, 80 and over (7) 7
breast neoplasms - metabolism (7) 7
neoplasm staging (7) 7
time factors (7) 7
abridged index medicus (6) 6
breast neoplasms - drug therapy (6) 6
carcinoma (6) 6
chemotherapy, adjuvant (6) 6
follow-up studies (6) 6
mutation (6) 6
predictive value of tests (6) 6
skin neoplasms - pathology (6) 6
treatment outcome (6) 6
antineoplastic agents - therapeutic use (5) 5
biomarkers (5) 5
biopsy (5) 5
breast neoplasms - genetics (5) 5
medicine & public health (5) 5
melanoma - pathology (5) 5
metastasis (5) 5
neoplasm metastasis (5) 5
retrospective studies (5) 5
risk factors (5) 5
survival (5) 5
survival rate (5) 5
biomarkers, tumor - metabolism (4) 4
breast cancer (4) 4
breast neoplasms - surgery (4) 4
chemotherapy (4) 4
dermatology (4) 4
disease-free survival (4) 4
expression (4) 4
melanoma - drug therapy (4) 4
neoplasm invasiveness (4) 4
pathology (4) 4
proportional hazards models (4) 4
prospective studies (4) 4
protein kinase inhibitors - adverse effects (4) 4
recurrence (4) 4
surgery (4) 4
tumors (4) 4
adenocarcinoma - pathology (3) 3
adenocarcinoma - surgery (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
biomarkers, tumor - analysis (3) 3
biomarkers, tumor - genetics (3) 3
braf (3) 3
cancer therapies (3) 3
carcinoma, squamous cell - chemically induced (3) 3
cell line, tumor (3) 3
cetuximab (3) 3
colorectal cancer (3) 3
colorectal neoplasms - genetics (3) 3
growth-factor receptor (3) 3
indoles - adverse effects (3) 3
local recurrence (3) 3
melanoma - therapy (3) 3
multivariate analysis (3) 3
proto-oncogene proteins b-raf - antagonists & inhibitors (3) 3
receptor, epidermal growth factor - metabolism (3) 3
rectal adenocarcinoma (3) 3
rectal neoplasms - pathology (3) 3
rectal neoplasms - surgery (3) 3
sensitivity and specificity (3) 3
skin neoplasms - chemically induced (3) 3
skin neoplasms - drug therapy (3) 3
sulfonamides - adverse effects (3) 3
surgical oncology (3) 3
1st-line treatment (2) 2
activation (2) 2
adolescent (2) 2
algorithms (2) 2
analysis (2) 2
animals (2) 2
anterior resection (2) 2
antibodies (2) 2
antibodies, monoclonal, humanized (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
antibody (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents, hormonal - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 11/2014, Volume 515, Issue 7528, pp. 568 - 571
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 513, Issue 7516, pp. 105 - 109
In BRAF(V600)-mutant tumours, most mechanisms of resistance to drugs that target the BRAF and/or MEK kinases rely on reactivation of the RAS-RAF-MEK-ERK... 
MESSENGER-RNA TRANSLATION | SILVESTROL | MELANOMA | INITIATION | RAF | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | LEUKEMIA-CELLS | MODEL | FEEDBACK INHIBITION | Triterpenes - pharmacology | Humans | Eukaryotic Initiation Factor-4E - metabolism | Eukaryotic Initiation Factor-4G - metabolism | Eukaryotic Initiation Factor-4F - metabolism | Melanoma - genetics | Protein Binding - drug effects | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Phosphorylation - drug effects | Eukaryotic Initiation Factor-4F - antagonists & inhibitors | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Sulfonamides - pharmacology | Eukaryotic Initiation Factor-4A - antagonists & inhibitors | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | MAP Kinase Signaling System - drug effects | Eukaryotic Initiation Factor-4F - chemistry | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Melanoma - drug therapy | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Eukaryotic Initiation Factor-4A - metabolism | Drug Resistance, Neoplasm - drug effects | Thyroid Neoplasms - pathology | Antimitotic agents | Pharmaceutical research | Vemurafenib | Protein research | Research | Antineoplastic agents | Drug resistance | Phosphorylation | Biopsy | Melanoma | Mutation | Metastasis | Cancer therapies | Tumors | Cancer | Index Medicus | Cell and Molecular Biology | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Cell- och molekylärbiologi | Medicinska och farmaceutiska grundvetenskaper
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 116, pp. 178 - 181
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2008, Volume 26, Issue 3, pp. 374 - 379
Journal Article
Journal Article
Journal Article
Annales de Pathologie, ISSN 0242-6498, 02/2017, Volume 37, Issue 1, pp. 55 - 60
Prognosis and treatment of advanced melanoma have been transformed by the success of immunotherapies, in particular agents targeting PD-1. PD-L1 expression... 
Immunotherapies | Melanoma | Biomarkers | PD-L1 | PD-1
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 01/2017, Volume 77, Issue 2, pp. 557 - 565
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2012, Volume 18, Issue 1, pp. 263 - 272
Journal Article
Journal Article
Virology, ISSN 0042-6822, 2012, Volume 426, Issue 2, pp. 134 - 142
Journal Article
Journal Article